Alisertib (MLN8237)

目录号:S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。

规格 价格 库存 购买数量  
RMB 1375.12 现货
RMB 983.87 现货
RMB 1725.78 现货
RMB 5505.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献48篇:

客户使用该产品的12个实验数据:

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。
特性 MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。
靶点
Aurora A [1]
(Cell-free assay)
1.2 nM
体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍,IC50为396.5 nM, 而对205种其他激酶则没有显著活性。[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞,抑制 Aurora A磷酸化,而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系,显著抑制细胞增殖,IC50为0.003-1.71 μM。在BM 基质细胞,IL-6和 IGF-1 存在时,MLN8237作用于原代MM 细胞和MM细胞系,抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系,使G2/M 期细胞提高2到6倍,且显著诱导凋亡和衰老,涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用,具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系,抑制集落形成,且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高,与单独用药相比,诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jMblAvPSEQvF2= NXTz[pM4PzJiaB?= M4PLVmROW09? MUTJR|UxRTBwMESg{txO NGLBNm4zPjF|Nk[4OC=>
LS174T NFzXTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\NU2ExNjVizszN NYXFZYtxPzJiaB?= NHvpVoZFVVOR M1L0XGlEPTB;MD6wOUDPxE1? NWi4RVdUOjZzM{[2PFQ>
T84 NH3ofFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPFNE42KM7:TR?= NGHFUlI4OiCq Ml7uSG1UVw>? M1jmcGlEPTB;MD6wPUDPxE1? M3vQTlI3OTN4Nki0
LS180 NWP6do5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqwMlUh|ryP NWfTOItrPzJiaB?= NWXiOpVLTE2VTx?= M3XGfmlEPTB;MTFOwG0> NH32V3UzPjF|Nk[4OC=>
SW948 M3;4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTWGkxNjVizszN NUToO3hHPzJiaB?= NEToPZhFVVOR NYrBd3pwUUN3ME2xJO69VQ>? MV:yOlE{PjZ6NB?=
HCT15 M3WwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37xW|AvPSEQvF2= MXW3NkBp MoTuSG1UVw>? MYPJR|UxRDBwNDFOwG0> MV[yOlE{PjZ6NB?=
DLD-1 NXfJb|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xo[FAvPSEQvF2= M1LiclczKGh? MVfEUXNQ NEm4TJFKSzVyPECuPEDPxE1? MVWyOlE{PjZ6NB?=
MIP-101 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwTYR2OC53IN88US=> M3PqZVczKGh? MofnSG1UVw>? Mm\wTWM2OD1zIN88US=> NXPDSJNyOjZzM{[2PFQ>
SNU1544 M4noRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKwMlUh|ryP NXm4S5d4PzJiaB?= NXLNeI45TE2VTx?= MX;JR|UxRTFizszN MmnQNlYyOzZ4OES=
OCI-Ly10 NFrPZlJEgXSxdH;4bYMhSXO|YYm= MnnZO|IhcA>? MmP2SG1UVw>? M4XvS2lEPTB;MD6wOVgh|ryP MXeyOVg4QDN|MR?=
SU-DHL2 NGPnblFEgXSxdH;4bYMhSXO|YYm= NGfvTmY4OiCq MnrwSG1UVw>? MYLJR|UxRTBwMEGg{txO NXvSfmdQOjV6N{izN|E>
OCI-LY7 M1X4OmN6fG:2b4jpZ{BCe3OjeR?= Mn;vO|IhcA>? MoLvSG1UVw>? Mm\OTWM2OD1yLkC4NUDPxE1? MmLNNlU5Pzh|M{G=
SU-DHL6 M2HQTGN6fG:2b4jpZ{BCe3OjeR?= MXy3NkBp MUnEUXNQ M1XC[GlEPTB;MD60PFIh|ryP Mk\ENlU5Pzh|M{G=
Jeko-1 M33Ne2N6fG:2b4jpZ{BCe3OjeR?= MYm3NkBp NXLMeXRUTE2VTx?= M1PRfmlEPTB;MD6wNlkh|ryP MWSyOVg4QDN|MR?=
JVM-2 MU\DfZRwfG:6aXOgRZN{[Xl? Mle2O|IhcA>? MVzEUXNQ Mnj1TWM2OD1yLkCxJO69VQ>? MmH0NlU5Pzh|M{G=
Rec-1 M3XHe2N6fG:2b4jpZ{BCe3OjeR?= MX23NkBp NVvDUItTTE2VTx?= NX;sTG5CUUN3ME2wMlA5PyEQvF2= Mon1NlU5Pzh|M{G=
Z-138 MlvxR5l1d3SxeHnjJGF{e2G7 NV22eoVUPzJiaB?= MofzSG1UVw>? NH\rUnpKSzVyPUCuNFE{KM7:TR?= MWOyOVg4QDN|MR?=
H9 M13pTGN6fG:2b4jpZ{BCe3OjeR?= MYG3NkBp Ml24SG1UVw>? MXnJR|UxRTBwNjFOwG0> MV2yOVg4QDN|MR?=
HH MUjDfZRwfG:6aXOgRZN{[Xl? NIPyUJI4OiCq M2fKUWROW09? Mly5TWM2OD1yLkeg{txO NEf4[2YzPTh5OEOzNS=>
DND41 M2jNVWN6fG:2b4jpZ{BCe3OjeR?= NHX0VWw4OiCq M{njZmROW09? MXfJR|UxRTBwMTFOwG0> NF32NVYzPTh5OEOzNS=>
CCL119 M4DDZ2N6fG:2b4jpZ{BCe3OjeR?= NUnrWIZoPzJiaB?= MVnEUXNQ NXrNfXZCUUN3ME2wMlA3OiEQvF2= M{TqPVI2QDd6M{Ox
J.Cam 1.6 Mn\oR5l1d3SxeHnjJGF{e2G7 MlT4O|IhcA>? M2rrUWROW09? MVnJR|UxRTBwMUC1JO69VQ>? NH\ab4czPTh5OEOzNS=>
Sup-T1 NHHKSHNEgXSxdH;4bYMhSXO|YYm= MVq3NkBp M17SSmROW09? NXP1SJI6UUN3ME2yMlE1OiEQvF2= NFLPZpgzPTh5OEOzNS=>
Tib 152 M{[3eWN6fG:2b4jpZ{BCe3OjeR?= MX:3NkBp NWL2b4VtTE2VTx?= M{LuR2lEPTB;MD64JO69VQ>? NIK1b2QzPTh5OEOzNS=>
MCF7 NYC0WXQ2TnWwY4Tpc44hSXO|YYm= MVK1JO69VQ>? MYqyOEBp MVPEUXNQ MX;JcoR2[2W|IFeyM20h[XK{ZYP0 NH65NpkzPTh|NESwNS=>
MDA-MB-231 NIWyNFlHfW6ldHnvckBCe3OjeR?= NIPMem02KM7:TR?= NV\6b2J5OjRiaB?= M1nUb2ROW09? NGHzVIhKdmS3Y3XzJGc{N01iYYLy[ZN1 M{LuXVI2QDN2NECx
MCF7 M{TIRWZ2dmO2aX;uJGF{e2G7 NHPQdpI2KM7:TR?= Ml7BNlQhcA>? MUnEUXNQ MXfE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ M4LuZ|I2QDN2NECx
MCF7 NUGyTZhtTnWwY4Tpc44hSXO|YYm= M{LOVlUh|ryP NUj3e4NOOjRiaB?= NWX4TGpyTE2VTx?= NX75NpJ1TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? M370dlI2QDN2NECx
MCF7 MmPzSpVv[3Srb36gRZN{[Xl? NVy4eoNuPSEQvF2= MnOxNlQhcA>? NX70T4x3TE2VTx?= NWewNW86TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> MYiyOVg{PDRyMR?=
MCF7 NIHEfZFHfW6ldHnvckBCe3OjeR?= NI\vcZo2KM7:TR?= NW\DeWJJOjRiaB?= M2[zWWROW09? MV\JcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> MoXINlU5OzR2MEG=
MCF7 MVPGeY5kfGmxbjDBd5NigQ>? Mlv1OUDPxE1? NXvhbIt5OjRiaB?= MlXtSG1UVw>? M1freGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= Ml;GNlU5OzR2MEG=
MDA-MB-231 NIrSe4pHfW6ldHnvckBCe3OjeR?= Mn3XOUDPxE1? NGn0UYEzPCCq NFLnWWFFVVOR NWf4S5pmTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> MnLSNlU5OzR2MEG=
MDA-MB-231 M3PKdGZ2dmO2aX;uJGF{e2G7 NELoZ|QyKM7:TR?= MnvZNlQhcA>? MXvEUXNQ NYOzXlY4UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? NH;ORYUzPTh|NESwNS=>
MDA-MB-231 Mm\ZSpVv[3Srb36gRZN{[Xl? NELQV2E2KM7:TR?= Mm\4NlQhcA>? MnjzSG1UVw>? MXHE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz M4X6eVI2QDN2NECx
MDA-MB-231 M2[zPWZ2dmO2aX;uJGF{e2G7 NGO3UpA2KM7:TR?= MmXINlQhcA>? MYjEUXNQ MX\JcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> NYXGS|dkOjV6M{S0NFE>
MDA-MB-231 M3ezOGZ2dmO2aX;uJGF{e2G7 NXLn[4RVPSEQvF2= NYf3T4tSOjRiaB?= M{Ly[GROW09? Ml\XTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz Ml[1NlU5OzR2MEG=
MDA-MB-231 NVPmSYF7TnWwY4Tpc44hSXO|YYm= MX[1JO69VQ>? Ml\GNlQhcA>? Mor1SG1UVw>? NIrod|VKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFU{ NELnRogzPTh|NESwNS=>
MCF7 NWnLNVkxSXCxcITvd4l{KEG|c3H5 NYK4[WhHPSEQvF2= MX[yOEBp M1PXb2ROW09? NXnKdJBOUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= MWCyOVg{PDRyMR?=
MDA-MB-231 MWDBdI9xfG:|aYOgRZN{[Xl? NETZXnE2KM7:TR?= NXzjO3l[OjRiaB?= MkPISG1UVw>? M1vGZmlv\HWlZYOgZZBweHSxdHnjJIRm[XSq M2TmTlI2QDN2NECx
MCF7 NVL5Rm8xTnWwY4Tpc44hSXO|YYm= NYOwc5BCOSEQvF2= NELNd3g4OiCq NYjjUYVvTE2VTx?= NUjyc|ZxUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo NHnpeI4zPTh|NESwNS=>
MDA-MB-231 MY\GeY5kfGmxbjDBd5NigQ>? Mom5NUDPxE1? NHiyeXc4OiCq NUXFR5k3TE2VTx?= MWLJcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? NHH0cG0zPTh|NESwNS=>
U-2 OS NFXOTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu1NEDPxE1? MnXLNlQhcA>? NW[yWGM1TE2VTx?= MWHJR|UxRTF4Lk[g{txO M4D5NFI2Pzl{OEGx
MG-63 NHHjepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXK1NEDPxE1? MYGyOEBp MUDEUXNQ M3XRPGlEPTB;OT61JO69VQ>? NXrxO2JoOjV5OUK4NVE>
U-2 OS NEX1U3NCeG:ydH;zbZMhSXO|YYm= MkfsOUDPxE1? Mmm0NlQhcA>? NX3WPGFWTE2VTx?= NWXxVXA1UW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? MmHwNlU4QTJ6MUG=
MG-63 MX\BdI9xfG:|aYOgRZN{[Xl? MkPWOUDPxE1? M3rhNFI1KGh? Mn72SG1UVw>? M2\Wdmlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> NH;oSWIzPTd7MkixNS=>
U-2 OS MULGeY5kfGmxbjDBd5NigQ>? NFLvenM2KM7:TR?= NEPIc2EzPCCq MYrEUXNQ NV;6S40zWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MXqyOVc6OjhzMR?=
MG-63 Mo\4SpVv[3Srb36gRZN{[Xl? NYH5VmpxPSEQvF2= M1SzOVI1KGh? NGXaRXNFVVOR MUXQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> MoDrNlU4QTJ6MUG=
PANC-1 M4nscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrzOVAh|ryP Ml;GNlQhcA>? MVfEUXNQ MmryTWM2OD15LkGg{txO NXvQd2R[OjV4M{KyNlU>
BxPC-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M12zT|UxKM7:TR?= M1LVbFI1KGh? MorvSG1UVw>? NF\RNmhKSzVyPU[uPEDPxE1? NEDoVI8zPTZ|MkKyOS=>
PANC-1 NHPUNpFHfW6ldHnvckBCe3OjeR?= MnflOUDPxE1? MmXsNlQhcA>? MYPEUXNQ MXXJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> M1XDe|I2PjN{MkK1
BxPC-3 NEWwb2RHfW6ldHnvckBCe3OjeR?= MlqyOUDPxE1? NVu1[oFOOjRiaB?= NX\uU443TE2VTx?= MYjJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> MoLKNlU3OzJ{MkW=
PANC-1 NXzDdXhyTnWwY4Tpc44hSXO|YYm= MX[1JO69VQ>? MoHuNlQhcA>? NH74bHVFVVOR NFHyflRKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? MYiyOVY{OjJ{NR?=
BxPC-3 NFrZXJVHfW6ldHnvckBCe3OjeR?= MoW4OUDPxE1? NWXVdXBDOjRiaB?= Mk\YSG1UVw>? M{iybmlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MkK4NlU3OzJ{MkW=
SKOV3 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfkNVAxKM7:TR?= MVGyOEBp MWXEUXNQ NFKzXZJKSzVyPUKwMlQ5KM7:TR?= NEDLbVMzPTZ{NEe1NC=>
OVCAR4 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTUboxvOTByIN88US=> MX2yOEBp MYXEUXNQ MXLJR|UxRTJ{LkGzJO69VQ>? M3e1VlI2PjJ2N{Ww
SKOV3 MVXGeY5kfGmxbjDBd5NigQ>? NGnpSGQ2KM7:TR?= MYq3NkBp MWnEUXNQ MlzZTY5lfWOnczDHNk9OKGG{cnXzeC=> NGSyR5EzPTZ{NEe1NC=>
OVCAR4 MkO5SpVv[3Srb36gRZN{[Xl? MWq1JO69VQ>? NUPPO|hnPzJiaB?= M3L0OmROW09? MkXrTY5lfWOnczDHNk9OKGG{cnXzeC=> NIjPfGMzPTZ{NEe1NC=>
SKOV3 NV73TXZ{SXCxcITvd4l{KEG|c3H5 NEXxbIk2KM7:TR?= NFriR2ozPCCq MYLEUXNQ NX\Ccpc4UW6mdXPld{BieG:ydH;zbZM> MWGyOVYzPDd3MB?=
OVCAR4 NILPcoRCeG:ydH;zbZMhSXO|YYm= MVO1JO69VQ>? NXTubpdJOjRiaB?= NX;aNFVxTE2VTx?= MXXJcoR2[2W|IHHwc5B1d3Orcx?= MWWyOVYzPDd3MB?=
AGS M1;s[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT5dZo6OjVizszN NGTybZgzPCCq NYXBc2NvTE2VTx?= NGfUSFRKSzVyPUG5MlA6KM7:TR?= MkHoNlU3ODl7MkO=
NCI-N78 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj1R41[OjVizszN MUeyOEBp MV7EUXNQ NVvqS|FOUUN3ME2yOk4{OyEQvF2= NIHuS5EzPTZyOUmyNy=>
AGS NEL2N4hCeG:ydH;zbZMhSXO|YYm= NULK[5FFPSEQvF2= MUWyOEBp M4mye2ROW09? NIC5R3lKdmS3Y3XzJIFxd3C2b4Ppdy=> NYrYcZJpOjV4MEm5NlM>
NCI-N78 MYXBdI9xfG:|aYOgRZN{[Xl? M1jjelUh|ryP NUf3OZVVOjRiaB?= M3uyUWROW09? MWPJcoR2[2W|IHHwc5B1d3Orcx?= NGjaW2YzPTZyOUmyNy=>
AGS M{nMfmZ2dmO2aX;uJGF{e2G7 M4eyN|Uh|ryP NX63boVXOjRiaB?= MWDEUXNQ NELjc25KdmS3Y3XzJJRp\SCjdYTvdIhi\3l? MmfyNlU3ODl7MkO=
NCI-N78 NVTPRYI4TnWwY4Tpc44hSXO|YYm= NEDYbnM2KM7:TR?= NHjCdHMzPCCq NIGwc2VFVVOR M2HKPGlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? MV[yOVYxQTl{Mx?=
HSC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fVR|Eh|ryP NIPMeWI1QCCq M{jpeWlEPTB;MD61OEDPxE1? NYi3cVJVOjV|Nk[xOFM>
GB30 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixJO69VQ>? MWS3JIQ> NHvGWJJFVVOR NF;tV|dKSzVyPUCuNFEyKM7:TR?= M{flTFI2OTB4NEK4
GB9 M2jXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xJO69VQ>? MUm3JIQ> NVviWWlvTE2VTx?= NGH5Z25KSzVyPUCuNFI1KM7:TR?= MXqyOVExPjR{OB?=
GB169 NX\OTm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;NPFEh|ryP MUO3JIQ> M4\RdmROW09? M37JPGlEPTB;MD6wN|Ih|ryP MWqyOVExPjR{OB?=
T24 M3yzRmZ2dmO2aX;uJGF{e2G7 NHfOdIYyKM7:TR?= NY[yXHh5PDhiaB?= MVHEUXNQ MWfJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M2HBOFI{PDB|NkOz
RT4 M3PVcWZ2dmO2aX;uJGF{e2G7 M2W0TVEh|ryP M1vT[lQ5KGh? NYTpfYhFTE2VTx?= M33kPGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= M{DBZlI{PDB|NkOz
UM-UC-3 MlHXSpVv[3Srb36gRZN{[Xl? MmXwNUDPxE1? MmHwOFghcA>? M4HDfWROW09? MXPJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NVvEZ2ZNOjN2MEO2N|M>
T24 MYrBdI9xfG:|aYOgRZN{[Xl? MnXHN{4yPiEQvF2= MkPmPVYhcA>? MVTEUXNQ NVXScXB1UUN3ME2wMlA{ODZizszN M3XzO|I{PDB|NkOz
RT4 NVzK[ZprSXCxcITvd4l{KEG|c3H5 M2\qUVMvOTZizszN M1nVVVk3KGh? NWLZVpJJTE2VTx?= MlLhTWM2OD1yLkGxPVgh|ryP MW[yN|QxOzZ|Mx?=
UM-UC-3 MnjuRZBweHSxc3nzJGF{e2G7 MnnVN{4yPiEQvF2= M3HyO|k3KGh? MXzEUXNQ NXfscGdsUUN3ME2wMlA1PDlizszN NWLtbHhnOjN2MEO2N|M>
OVCAR-5 NEnoZmxHfW6ldHnvckBCe3OjeR?= NEHNSXA2OCCwTR?= MoT2TY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? NELM[JYzOzN|NEOyOy=>
SKOV3ip2 NVfwVGF1TnWwY4Tpc44hSXO|YYm= MVm1NEBvVQ>? M3\HemlvcGmkaYTzJINmdGxibXnndoF1cW:w NYTkS2FTOjN|M{SzNlc>
S462 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLXXHIyODBizszN MYC3NkBp MkjISG1UVw>? NFfzd|FCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NW\ZcYR4OjN|MkixNVQ>
2884 M3mxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNFAh|ryP NV3FZ3N4PzJiaB?= M{PXS2ROW09? MVHBeJRmdnWjdHXzJINmdGxiZ4Lve5Rp NXnsTWZiOjN|MkixNVQ>
2885 NWrPfHp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M375RVExOCEQvF2= MlnkO|IhcA>? M3e1W2ROW09? M4DjV2F1fGWwdXH0[ZMh[2WubDDndo94fGh? Mk\BNlM{OjhzMUS=
CRL-2396 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;iencyODBizszN M3q2bJdifGW{ NXf4ZZpDUUN3ME2wMlA6OiEQvF2= NHGyO4wzOzF3M{WyOC=>
TIB-48 NGX5Z|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULLWodEOTByIN88US=> M{PUU5difGW{ NFXOXZpKSzVyPUCuNFg5KM7:TR?= M{Poc|I{OTV|NUK0
CRL-2396 MW\DfZRwfG:6aXOgRZN{[Xl? NITObWUyKM7:TR?= M3jsWVQ5KGh? MYj3ZZRmeg>? NU\aeo91UW6mdXPld{BieG:ydH;zbZM> NHzlZlYzOzF3M{WyOC=>
TIB-48 NGrFXZlEgXSxdH;4bYMhSXO|YYm= NH34fY0yKM7:TR?= MXK0PEBp NXvoXWptf2G2ZYK= MXPJcoR2[2W|IHHwc5B1d3Orcx?= NYHOfmtFOjNzNUO1NlQ>
AGS NUDibmY2S3m2b4TvfIlkKEG|c3H5 NW\Yd|VsOC53IN88US=> MVyyOEBp MV3EUXNQ MnPPSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NITGT3czOjl5Mk[xNS=>
FLO-1 MV\DfZRwfG:6aXOgRZN{[Xl? MUOwMlUh|ryP MWGyOEBp MkjoSG1UVw>? M1faXWRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu M1TVUVIzQTd{NkGx
OE33 NUf0[IJHS3m2b4TvfIlkKEG|c3H5 NXexcYJnOC53IN88US=> NXuzbm1kOjRiaB?= MWrEUXNQ NFTxR4lF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= NEC3OZEzOjl5Mk[xNS=>
SKLMS MYXDfZRwfG:6aXOgRZN{[Xl? NGK0UXI4PSCwTR?= NEfte2c6PiCq NFfCcYlKdmS3Y3XzJIFxd3C2b4Ppdy=> MUiyNlgzOTl7Nx?=
Leio285 MnP6R5l1d3SxeHnjJGF{e2G7 NF\L[2Y4PSCwTR?= M1HqfFk3KGh? MVrJcoR2[2W|IHHwc5B1d3Orcx?= NF3QXGwzOjh{MUm5Oy=>
Mes-Sa MkfHR5l1d3SxeHnjJGF{e2G7 MY[3OUBvVQ>? NXPuZmQ4QTZiaB?= MnO3TY5lfWOnczDhdI9xfG:|aYO= MVyyNlgzOTl7Nx?=
DAOY M4DmWmN6fG:2b4jpZ{BCe3OjeR?= MoPPNVAh|ryP NGfoOZY4OiCq MWXEUXNQ MlLBTWM2OD1yLkC0JO69VQ>? M3XDVFIzPjZ7M{O1
IMR32 MlTVR5l1d3SxeHnjJGF{e2G7 NHXIOo0yOCEQvF2= MU[3NkBp MVHEUXNQ MUPJR|UxRTBwMEOg{txO MmHENlI3Pjl|M{W=
Molt-4 NVfNR5V7S3m2b4TvfIlkKEG|c3H5 MXOxNEDPxE1? NHe0XZI4OiCq MorPSG1UVw>? NXLlW2E3UUN3ME2wMlAzKM7:TR?= MmnaNlI3Pjl|M{W=
MOLM-13 M{PM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHwN{DPxE1? NVT3fpZUPzJiaB?= M2XjZWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NXvDR3pTOjJ2OEiyOFk>
HL-60 Ml3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYizJO69VQ>? NEDLWXg4OiCq MVTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M1zYVlIzPDh6MkS5
MV4-11 NWLPdlFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\nVmE{KM7:TR?= MUK3NkBp NYXOUG0yTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NUDQcmN7OjJ2OEiyOFk>
SKM-1 NYDw[W1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq2e3M{KM7:TR?= NEPyXmQ4OiCq NHTXTZRFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MXiyNlQ5QDJ2OR?=
SH2 NVS1W4xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqzJO69VQ>? MYC3NkBp MYLEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NHuzVVUzOjR6OEK0PS=>
NOMO-1 NYTn[3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS4PZo{KM7:TR?= NHHtXZE4OiCq NW\QdJd3TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M{DNUFIzPDh6MkS5
OCL-AML2 NGXNfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\3N{DPxE1? Mm[wO|IhcA>? MYHEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MnrLNlI1QDh{NEm=
PL-21 M4XEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\lNWxTOyEQvF2= M4PuUFczKGh? MYnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MoDLNlI1QDh{NEm=
KG-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn1RWxmOyEQvF2= MWm3NkBp NH3qWI5FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MoLNNlI1QDh{NEm=
A172 NX\iO21ZS3m2b4TvfIlkKEG|c3H5 NXHoSHl{OTByIN88US=> M3O3[lI1KGh? NV\yUWxUTE2VTx?= M4D0Z2lEPTB;MD6xNlAh|ryP MUGyNlI4PDN7OR?=
U87 M1XnemN6fG:2b4jpZ{BCe3OjeR?= NFH5SIYyODBizszN NIfEeHUzPCCq NHH2XYlFVVOR NELlPFdKSzVyPUCuNVA2KM7:TR?= MnewNlIzPzR|OUm=
U251 M1Xo[WN6fG:2b4jpZ{BCe3OjeR?= NGnxdHAyODBizszN M4rLNFI1KGh? NILpcJpFVVOR NIPIR2hKSzVyPUCuNVAxKM7:TR?= NXT4b5NrOjJ{N{SzPVk>
T98 NITzfmZEgXSxdH;4bYMhSXO|YYm= NYnqSG82OTByIN88US=> M3zWO|I1KGh? MXLEUXNQ MXTJR|UxRTBwMUK1JO69VQ>? M1;nRlIzOjd2M{m5
LN18 Mni5R5l1d3SxeHnjJGF{e2G7 NUP4Z4s2OTByIN88US=> MkKxNlQhcA>? MX7EUXNQ M{DIb2lEPTB;MD6yNVAh|ryP M{PrcVIzOjd2M{m5
LN443 NHOyPZpEgXSxdH;4bYMhSXO|YYm= MWmxNFAh|ryP M4PnNFI1KGh? MXrEUXNQ MVfJR|UxRTBwMkKwJO69VQ>? M3HCbVIzOjd2M{m5
HF66 MoXjR5l1d3SxeHnjJGF{e2G7 MXWxNFAh|ryP M{T1flI1KGh? MVzEUXNQ NEf1[IdKSzVyPUCuNlI2KM7:TR?= NU\Rb2h7OjJ{N{SzPVk>
HF2303 NW\zNHpDS3m2b4TvfIlkKEG|c3H5 MYCxNFAh|ryP MlzoNlQhcA>? NG[1RZBFVVOR NHjic3lKSzVyPUCuNFYxKM7:TR?= NVnVSHdjOjJ{N{SzPVk>
HF2359 MWnDfZRwfG:6aXOgRZN{[Xl? Mne2NVAxKM7:TR?= Ml6xNlQhcA>? M3XJfGROW09? NFmzUGRKSzVyPUCuNFYxKM7:TR?= MnrNNlIzPzR|OUm=
HF2414 NFP3[ZNEgXSxdH;4bYMhSXO|YYm= NF3kTWwyODBizszN M1nlNFI1KGh? MVvEUXNQ NXjFdG5xUUN3ME2wMlA5OCEQvF2= M1TSUFIzOjd2M{m5
A-673 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lSlExKM7:TR?= NXvTTGNDQTZiaB?= M2PMdmROW09? Ml3BTWM2OD1yLkCzNkDPxE1? NXvpc4tlOjF2NEi1PVE>
TC-32 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHPZY5wOTBizszN MmrhPVYhcA>? NF7yZYFFVVOR NGjUSXdKSzVyPUCuNFM6KM7:TR?= Mny0NlE1PDh3OUG=
TC-71 M4TTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTE[|cyOCEQvF2= MnrRPVYhcA>? MUDEUXNQ M4HOVmlEPTB;MD6xNFIh|ryP NHOxdZUzOTR2OEW5NS=>
SK-N-MC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5NVAh|ryP MmXhPVYhcA>? M1q1VmROW09? M4TwNmlEPTB;MD6wO|Ih|ryP NH[zWYozOTR2OEW5NS=>
CHLA-9 M1jFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PiSFExKM7:TR?= M2rZc|k3KGh? M2jaemROW09? M1LZVWlEPTB;MD6wNVgh|ryP MYiyNVQ1QDV7MR?=
CHLA-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqwNVAh|ryP MonaPVYhcA>? MVfEUXNQ NYHlfWF2UUN3ME2wMlA3OCEQvF2= M{nTPFIyPDR6NUmx
CHLA-25 NFzaT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LLfVExKM7:TR?= NF3CeJk6PiCq NFjNWWhFVVOR M3HyemlEPTB;MD6xOlgh|ryP Mli3NlE1PDh3OUG=
CHLA-32 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNEDPxE1? MYi5OkBp MoDHSG1UVw>? Mlq3TWM2OD1yLkGzOkDPxE1? NYTZbpYyOjF2NEi1PVE>
CHLA-56 NHTZSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xNEDPxE1? NG\mPJY6PiCq MVHEUXNQ NVTWVJVEUUN3ME2xNEDPxE1? NGPVeo8zOTR2OEW5NS=>
CHLA-258 M2jHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pNVAh|ryP Mln3PVYhcA>? NILTS41FVVOR NGm3eXlKSzVyPUCuNVMzKM7:TR?= MV6yNVQ1QDV7MR?=
COG-E-352 M{HrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLUXYJQOTBizszN MnrOPVYhcA>? M{TsOGROW09? M1;icGlEPTB;MD6wOFMh|ryP NXzmTnEyOjF2NEi1PVE>
CHLA-90 M{fTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;FPFExKM7:TR?= M3vucVk3KGh? NGTLcXFFVVOR Ml;jTWM2OD1yLkC2NUDPxE1? NIO1dXQzOTR2OEW5NS=>
CHLA-119 NUnSdZlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfZNVAh|ryP Mm\0PVYhcA>? NELJSVZFVVOR NYLtRY14UUN3ME2wMlAzOiEQvF2= MUKyNVQ1QDV7MR?=
CHLA-122 NH\SRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfXdWRjOTBizszN Ml\uPVYhcA>? NILaUotFVVOR NYrkeWI1UUN3ME2wMlAyQSEQvF2= MYSyNVQ1QDV7MR?=
CHLA-136 NVnKXFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P3PFExKM7:TR?= NGjGbIg6PiCq NITMfWdFVVOR MnHXTWM2OD1yLkCzPUDPxE1? M2j3bVIyPDR6NUmx
CHLA-140 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfMZ5N3OTBizszN M1ztSVk3KGh? M4PxbWROW09? NFHUbllKSzVyPUCuNFI3KM7:TR?= MkL1NlE1PDh3OUG=
LA-N-6 M1flO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSxNEDPxE1? Ml;YPVYhcA>? NF;aRW9FVVOR NYKyT|NEUUN3ME2wMlA2PCEQvF2= NInxfZYzOTR2OEW5NS=>
NB-1643 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vqdlExKM7:TR?= MmfPPVYhcA>? MVPEUXNQ NUjNNJg4UUN3ME2wMlA{PyEQvF2= NXvUb5FjOjF2NEi1PVE>
NB-EBc1 NH7XcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3UPXhOOTBizszN MWK5OkBp M3X1SmROW09? NHfmXZdKSzVyPUCuNFUxKM7:TR?= MViyNVQ1QDV7MR?=
SK-N-BE-1 M{nRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG1Z2UyOCEQvF2= MoLRPVYhcA>? NWK2boczTE2VTx?= NE\J[GJKSzVyPUCuNFI5KM7:TR?= M{S1dFIyPDR6NUmx
SK-N-BE-2 NWjmOmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KzeVExKM7:TR?= NGnYNo46PiCq NV3HR2Z{TE2VTx?= M4jk[WlEPTB;MD6wN|Yh|ryP M2\t[VIyPDR6NUmx
SMS-KAN M2\kT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXNNVAh|ryP NEjXTYc6PiCq NGPMNXVFVVOR NWLwVIw{UUN3ME2wMlA{PCEQvF2= MlmzNlE1PDh3OUG=
SMS-KANR MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXhXpFUOTBizszN MlW0PVYhcA>? NYDYSYlxTE2VTx?= NW\NNINvUUN3ME2wMlAzPiEQvF2= MWOyNVQ1QDV7MR?=
SMS-KCN NWLyWotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxNEDPxE1? MW[5OkBp NWXjb4poTE2VTx?= NFTJcVFKSzVyPUCuNFE6KM7:TR?= MX:yNVQ1QDV7MR?=
SMS-KCNR M{fGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WzTlExKM7:TR?= NHrXcYg6PiCq NUPKOnBuTE2VTx?= M4f5bWlEPTB;MD6wNVAh|ryP M{[zelIyPDR6NUmx
SMS-LHN M1j5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLXbJEyOCEQvF2= NGS3VFQ6PiCq Mk[2SG1UVw>? NITTR3FKSzVyPUCuNFMzKM7:TR?= MVSyNVQ1QDV7MR?=
SMS-MSN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjoUIloOTBizszN MoLsPVYhcA>? NV63d4xpTE2VTx?= MWPJR|UxRTBwMEKyJO69VQ>? M3zvbFIyPDR6NUmx
SMS-SAN M4fuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TvVVExKM7:TR?= MXK5OkBp MojCSG1UVw>? NVTEcmlSUUN3ME2wMlAzOCEQvF2= MWGyNVQ1QDV7MR?=
Granta-4 M2C5OWN6fG:2b4jpZ{BCe3OjeR?= M2L4RVExKM7:TR?= MUW3JIQ> NXvmSlNOUUN3ME2wMlA1OCEQvF2= Ml3MNlEzQTF6Nke=
DB Mm\jR5l1d3SxeHnjJGF{e2G7 M3fUblExKM7:TR?= NXXKT4x3PyCm NX\JR|BxUUN3ME2wMlA1OiEQvF2= Mlj5NlEzQTF6Nke=
RL M{f1bmN6fG:2b4jpZ{BCe3OjeR?= MkDyNVAh|ryP NGnveWM4KGR? M2Lp[mlEPTB;MD6wNVUh|ryP M{fYUFIyOjlzOE[3
K562 M4T4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrzNVAh|ryP M1W2XFk3KGh? MnHRTWM2OD1yLkC4O{DPxE1? MnHQNlExQTF4M{O=
LAMA-84 M3e4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNEDPxE1? M{PJNVk3KGh? M1:0[GlEPTB;MD6wOVch|ryP NGe5[44zOTB7MU[zNy=>
MM15 NYnwUIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPabJg1KM7:TR?= MUS3NkBp M1i4bmROW09? NUHpWYJ5UUN3ME2wMlE{KM7:TR?= MmTXNlA{QDJ6NES=
OPM1 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPPU41YPCEQvF2= NGriPWI4OiCq NUjuOHQ4TE2VTx?= NVfYUW02UUN3ME2wMlA{KM7:TR?= MX[yNFM5Ojh2NB?=
RPM1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTZOEDPxE1? NWT0VFVjPzJiaB?= NGrLfJNFVVOR M4WydGlEPTB;MUCuN|Ih|ryP NWj1T2VOOjB|OEK4OFQ>
INA6 NWrLemtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrpNok1KM7:TR?= NYrjfFM3PzJiaB?= M33kWWROW09? NEHselZKSzVyPUCuNFAzKM7:TR?= NUfM[|NNOjB|OEK4OFQ>
OPM2 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnOEDPxE1? NIDYfHc4OiCq MXvEUXNQ NVjR[JhiUUN3ME20MlM4KM7:TR?= NGfnSG8zODN6Mki0OC=>
MM1R M3vhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq0JO69VQ>? M3:4[|czKGh? NWC3ZVl{TE2VTx?= MX;JR|UxRTFwNkig{txO NVnNdFhUOjB|OEK4OFQ>
DOX40 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu0JO69VQ>? MVm3NkBp MYXEUXNQ NXW4e|BrUUN3ME21MlQ5KM7:TR?= M2jZZlIxOzh{OES0
LR5 NIfneplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SxUFQh|ryP M3uwO|czKGh? NF7VU2ZFVVOR NFK5ZXJKSzVyPUKuOVMh|ryP NHP3TlQzODN6Mki0OC=>
U266 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPPOoo1KM7:TR?= NV[5dYFGPzJiaB?= NVLlSpdYTE2VTx?= MlTiTWM2OD1zLkSzJO69VQ>? Mki5NlA{QDJ6NES=
RD MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfJW48yOCEQvF2= MlvJPVYhcA>? NETYUopKSzVyPUCuNlI5KM7:TR?= MYOyNFExQDN|OB?=
Rh41 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;WPFExKM7:TR?= MYC5OkBp MkK4TWM2OD1yLkC5NEDPxE1? NEGwRnIzODFyOEOzPC=>
Rh30 NYrudZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV31OIlbOTBizszN NXn0cG5TQTZiaB?= MU\JR|UxRTBwMkOwJO69VQ>? M1XVSVIxOTB6M{O4
BT-12 NVyxd|hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjINVAh|ryP M4fzeFk3KGh? NVXJT|E2UUN3ME2wMlA3OCEQvF2= NGTCUHQzODFyOEOzPC=>
CHLA-266 M3fHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXYfW0yOCEQvF2= NV31doR4QTZiaB?= MVPJR|UxRTBwMEeyJO69VQ>? M1\VSlIxOTB6M{O4
TC-71 M1jQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jxUVExKM7:TR?= MX:5OkBp MnTGTWM2OD1yLkGwNkDPxE1? M334fFIxOTB6M{O4
SJ-GBM2 NGHDPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnEeYgyOCEQvF2= Mn;PPVYhcA>? MV\JR|UxRTBwMEWwJO69VQ>? NYPIeod3OjBzMEizN|g>
NALM-6 NHX3R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTSbFIyOCEQvF2= M1\NNVk3KGh? M2XKRWlEPTB;MD6wOlIh|ryP M4\QUlIxOTB6M{O4
COG-LL-317 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXixNEDPxE1? NEXSeIs6PiCq MlywTWM2OD1yLkC0O{DPxE1? NG[5NJUzODFyOEOzPC=>
RS4-11 M4q2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj6cVZXOTBizszN NVfWUo56QTZiaB?= Mn7hTWM2OD1yLkCxPEDPxE1? NELnbGMzODFyOEOzPC=>
MOLT-4 M1jybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNEDPxE1? MoLmPVYhcA>? MVLJR|UxRTBwMEK2JO69VQ>? NF\VeGkzODFyOEOzPC=>
CCRF-CEM NV7Cc3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2xNEDPxE1? MYS5OkBp MkjWTWM2OD1yLkC5OEDPxE1? NUTjWm9kOjBzMEizN|g>
Kasumi-1 NIj3W|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTMN4pWOTBizszN NVK5Z5Z6QTZiaB?= NUT1U5JnUUN3ME2wMlExOyEQvF2= MVuyNFExQDN|OB?=
Karpas-299 NF;ldm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rjblExKM7:TR?= NWPY[WU{QTZiaB?= NVnVc4J1UUN3ME2wMlA{QCEQvF2= MXSyNFExQDN|OB?=
Ramos-RA1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNEDPxE1? MYO5OkBp MkjITWM2OD1yLkGyO{DPxE1? MV6yNFExQDN|OB?=

... Click to View More Cell Line Experimental Data

体内研究 MLN8237口服处理,显著降低肿瘤负担,按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比,延迟小鼠寿命。[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤,与单独用药相比,抗癌活性增强,伴随着Ki-67表达受抑制,细胞核p73蛋白和cleaved caspase 3表达增强。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

Aurora A放射性闪光板酶实验:

进行Aurora A放射性闪光板酶实验,测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A,然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-33 P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验:[2]
+ 展开
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266
  • Concentrations: 溶于DMSO,终浓度为~10 μM
  • Incubation Time: 24, 48, 和72小时
  • Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力,通过测定 3[3H]-胸甘渗透而测定细胞增殖。为了分析细胞周期,使用70%乙醇在-20oC下使细胞通透,然后与50 μg/mL PI 和20 单位/mL RNase-A温育。 通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。 为了测定凋亡和衰老,使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下接种 MM1.S 细胞的SCID鼠
  • Formulation: 在10% 2-羟丙基-β-环糊精/1%碳酸氢钠中配制
  • Dosages: ~30 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
15% Captisol
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 518.92
化学式

C27H20ClFN4O4

CAS号 1028486-01-2
稳定性 powder
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Alisertib (MLN8237) | Alisertib (MLN8237)供应商 | 采购Alisertib (MLN8237) | Alisertib (MLN8237)价格 | Alisertib (MLN8237)生产 | 订购Alisertib (MLN8237) | Alisertib (MLN8237)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID